280 related articles for article (PubMed ID: 29550629)
1. Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis.
Yalniz FF; Murad MH; Lee SJ; Pavletic SZ; Khera N; Shah ND; Hashmi SK
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1920-1927. PubMed ID: 29550629
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre.
Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL
Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056
[TBL] [Abstract][Full Text] [Related]
3. Development of a population-based cost-effectiveness model of chronic graft-versus-host disease in Spain.
Crespo C; Pérez-Simón JA; Rodríguez JM; Sierra J; Brosa M
Clin Ther; 2012 Aug; 34(8):1774-87. PubMed ID: 22835778
[TBL] [Abstract][Full Text] [Related]
4. Extracorporeal Photopheresis for Second-Line Treatment of Chronic Graft-versus-Host Diseases: Results from a Health Technology Assessment in Italy.
de Waure C; Capri S; Veneziano MA; Specchia ML; Cadeddu C; Di Nardo F; Ferriero AM; Gennari F; Hamilton C; Mancuso A; Quaranta G; Raponi M; Valerio L; Gensini G; Ricciardi W
Value Health; 2015 Jun; 18(4):457-66. PubMed ID: 26091600
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis.
Fan S; Huo WX; Yang Y; Shen MZ; Mo XD
Front Immunol; 2022; 13():954268. PubMed ID: 35990629
[TBL] [Abstract][Full Text] [Related]
6. Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease: An Italian Multicentric Retrospective Analysis on 94 Patients on Behalf of the Gruppo Italiano Trapianto di Midollo Osseo.
Malagola M; Cancelli V; Skert C; Leali PF; Ferrari E; Tiburzi A; Sala ML; Donnini I; Chiusolo P; Mussetti A; Battista M; Turra A; Cattina F; Rambaldi B; Schieppati F; Polverelli N; Bernardi S; Perucca S; Marini M; Laszlo D; Savignano C; Patriarca F; Corradini P; Piccirillo N; Sica S; Bosi A; Russo D
Transplantation; 2016 Dec; 100(12):e147-e155. PubMed ID: 27861297
[TBL] [Abstract][Full Text] [Related]
7. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
[TBL] [Abstract][Full Text] [Related]
8. [The clinical observation of sirolimus combined with calcineurin inhibitors for steroid-resistant/steroid-dependent extensive cGVHD].
Zhu W; Feng YM; Chen T; Yao H; Quan Y; Rao J; Gao L; Zhang C; Liu Y; Gao L; Kong PY; Zhang X
Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):716-722. PubMed ID: 33113602
[No Abstract] [Full Text] [Related]
9. Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies.
Abu-Dalle I; Reljic T; Nishihori T; Antar A; Bazarbachi A; Djulbegovic B; Kumar A; Kharfan-Dabaja MA
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1677-86. PubMed ID: 24867779
[TBL] [Abstract][Full Text] [Related]
10. A Single-center, Real-world Experience of Chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its Treatment Outcomes.
Linn SM; Novitzky-Basso I; Abduljalil O; Pasic I; Lam W; Law A; Michelis FV; Gerbitz A; Viswabandya A; Lipton J; Kumar R; Mattsson J; Kim DDH
Hematol Oncol Stem Cell Ther; 2023 Jul; 17(1):60-71. PubMed ID: 37581458
[TBL] [Abstract][Full Text] [Related]
11. Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis.
Malik MI; Litzow M; Hogan W; Patnaik M; Murad MH; Prokop LJ; Winters JL; Hashmi S
Blood Res; 2014 Jun; 49(2):100-6. PubMed ID: 25025011
[TBL] [Abstract][Full Text] [Related]
12. Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD.
Baek DW; Cho HJ; Kim JH; Ahn JS; Kim HJ; Lim SN; Cheong JW; Kim SY; Lee HS; Won JH; Yhim HY; Sohn SK; Moon JH
Cell Transplant; 2022; 31():9636897221113789. PubMed ID: 35861214
[TBL] [Abstract][Full Text] [Related]
13. Higher response rates in patients with severe chronic skin graft-versus-host disease treated with extracorporeal photopheresis.
Afram G; Watz E; Remberger M; Nygell UA; Sundin M; Hägglund H; Mattsson J; Uhlin M
Cent Eur J Immunol; 2019; 44(1):84-91. PubMed ID: 31114441
[TBL] [Abstract][Full Text] [Related]
14. A personalized, organ-based approach to the treatment of chronic steroid-refractory graft-versus-host disease.
Fatoum H; Zeiser R; Hashmi SK
Blood Rev; 2024 Jan; 63():101142. PubMed ID: 38087715
[TBL] [Abstract][Full Text] [Related]
15. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work?
Couriel D; Hosing C; Saliba R; Shpall EJ; Andelini P; Popat U; Donato M; Champlin R
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):37-40. PubMed ID: 16399600
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis.
Baccelli F; Gottardi F; Muratore E; Leardini D; Grasso AG; Gori D; Belotti T; Prete A; Masetti R
Bone Marrow Transplant; 2024 Feb; ():. PubMed ID: 38402346
[TBL] [Abstract][Full Text] [Related]
17. Early initiation of extracorporeal photochemotherapy increases response for chronic graft versus host disease following steroid failure.
Gunduz M; Atilla E; Atilla PA; Topcuoglu P; Ilhan O
Transfus Clin Biol; 2019 Feb; 26(1):32-37. PubMed ID: 29655590
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the CELLEX™ and UVAR-XTS™ closed-system extracorporeal photopheresis devices in the treatment of chronic graft-versus-host disease.
Whittle RM; Denney H; Chantry AD; Alfred A; Taylor PC
J Clin Apher; 2017 Dec; 32(6):462-473. PubMed ID: 28608529
[TBL] [Abstract][Full Text] [Related]
19. Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial.
Kitko CL; Braun T; Couriel DR; Choi SW; Connelly J; Hoffmann S; Goldstein S; Magenau J; Pawarode A; Reddy P; Schuler C; Yanik GA; Ferrara JL; Levine JE
Biol Blood Marrow Transplant; 2016 May; 22(5):862-8. PubMed ID: 26551636
[TBL] [Abstract][Full Text] [Related]
20. Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease.
Ilhan O; Arat M; Arslan O; Ayyildiz E; Sanli H; Beksac M; Ozcan M; Gürman G; Akan H
Transfus Apher Sci; 2004 Jun; 30(3):185-7. PubMed ID: 15172621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
